Skip to main content
Premium Trial:

Request an Annual Quote

Visby Medical Nabs FDA EUA for POC Respiratory Panel Test

NEW YORK – Visby Medical's respiratory panel test has received Emergency Use Authorization from the US Food and Drug Administration, according to a letter from the agency.

The RT-PCR assay simultaneously detects and differentiates between SARS-CoV-2, influenza A, and influenza B viral RNA in nasopharyngeal swab specimens from people suspected of respiratory viral infection consistent with COVID-19. The single-use test is authorized for use at the point of care and in laboratories that meet the requirements to perform high-, moderate-, or waived-complexity tests.

In 2021, the company received $12.3 million from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to develop a handheld diagnostic test for SARS-CoV-2 and influenza. Earlier this year, the company announced it would execute a $25.5 million contract option with the Office of the Assistant Secretary for Preparedness and Response in BARDA to develop an at-home version of the test. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.